Pseudo-obstruction, stroke, and mitochondrial dysfunction: A lethal combination

Yi Shiau Ng1, Catherine Feeney1, Andrew M Schaefer1

  • 1Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, United Kingdom.

Annals of Neurology
|July 26, 2016
PubMed
Abstract

Insights

Intestinal pseudo-obstruction (IPO) is an under-recognized complication of the common m.3243A>G mitochondrial disease mutation. Early recognition by neurologists is crucial, as stroke is a key predictor of IPO and poor outcomes, especially with surgery.

Area of Science:

  • Mitochondrial Medicine
  • Gastroenterology
  • Neurology

Background:

  • The m.3243A>G mutation in MTTL1 is the most prevalent cause of mitochondrial disease.
  • Intestinal pseudo-obstruction (IPO) is a recognized but under-appreciated complication of mitochondrial disorders.
  • Limited awareness exists regarding the prevalence and clinical impact of IPO in m.3243A>G mutation carriers.

Purpose of the Study:

  • To determine the prevalence and severity of IPO in patients with m.3243A>G mitochondrial disease.
  • To investigate the clinical outcomes associated with IPO in this patient cohort.
  • To identify predictors for the development of IPO in m.3243A>G mutation carriers.

Main Methods:

  • An observational cohort study of 226 patients with genetically confirmed m.3243A>G mutation.
  • Assessment of clinical, molecular, and radiological characteristics of patients presenting with IPO symptoms.
  • Retrospective analysis of patient data from January 2009 to June 2015.

Main Results:

  • Thirty patients (13%) presented with IPO; 13 had prior stroke-like episodes, and 8 developed IPO during a stroke-like episode.
  • Stroke was identified as the strongest predictor for IPO development, alongside cardiomyopathy, low BMI, and high urinary mutation load.
  • Six patients experienced poor clinical outcomes following surgical interventions for IPO.

Conclusions:

  • IPO is an under-recognized and often misdiagnosed clinical entity in m.3243A>G mitochondrial disease.
  • The strong association with stroke and poor outcomes after surgery underscores the need for high clinical suspicion.
  • Timely neurologist involvement and multidisciplinary care coordination are essential for optimal management of IPO in these patients.